Literature DB >> 29144496

Suppression from beyond the grave.

Yosuke Togashi1, Hiroyoshi Nishikawa2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29144496     DOI： 10.1038/ni.3870

Source DB:  PubMed          Journal:  Nat Immunol        ISSN： 1529-2908            Impact factor:   25.606


× No keyword cloud information.
  11 in total

Review 1.  Regulatory T cells exert checks and balances on self tolerance and autoimmunity.

Authors:  Kajsa Wing; Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2009-12-17       Impact factor: 25.606

2.  Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

Authors:  Corey J Langer; Shirish M Gadgeel; Hossein Borghaei; Vassiliki A Papadimitrakopoulou; Amita Patnaik; Steven F Powell; Ryan D Gentzler; Renato G Martins; James P Stevenson; Shadia I Jalal; Amit Panwalkar; James Chih-Hsin Yang; Matthew Gubens; Lecia V Sequist; Mark M Awad; Joseph Fiore; Yang Ge; Harry Raftopoulos; Leena Gandhi
Journal:  Lancet Oncol       Date:  2016-10-10       Impact factor: 41.316

Review 3.  Regulatory T cells in cancer immunotherapy.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2014-01-14       Impact factor: 7.486

4.  Detection of self-reactive CD8⁺ T cells with an anergic phenotype in healthy individuals.

Authors:  Yuka Maeda; Hiroyoshi Nishikawa; Daisuke Sugiyama; Danbee Ha; Masahide Hamaguchi; Takuro Saito; Megumi Nishioka; James B Wing; Dennis Adeegbe; Ichiro Katayama; Shimon Sakaguchi
Journal:  Science       Date:  2014-12-19       Impact factor: 47.728

Review 5.  FOXP3+ regulatory T cells in the human immune system.

Authors:  Shimon Sakaguchi; Makoto Miyara; Cristina M Costantino; David A Hafler
Journal:  Nat Rev Immunol       Date:  2010-06-18       Impact factor: 53.106

6.  Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Authors:  Emanuela Romano; Monika Kusio-Kobialka; Periklis G Foukas; Petra Baumgaertner; Christiane Meyer; Pierluigi Ballabeni; Olivier Michielin; Benjamin Weide; Pedro Romero; Daniel E Speiser
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

7.  Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor Engagement.

Authors:  Rony Dahan; Jeffrey V Ravetch
Journal:  Cancer Cell       Date:  2016-09-12       Impact factor: 31.743

Review 8.  Metabolic control of regulatory T cell development and function.

Authors:  Hu Zeng; Hongbo Chi
Journal:  Trends Immunol       Date:  2014-09-20       Impact factor: 16.687

9.  Two FOXP3(+)CD4(+) T cell subpopulations distinctly control the prognosis of colorectal cancers.

Authors:  Takuro Saito; Hiroyoshi Nishikawa; Hisashi Wada; Yuji Nagano; Daisuke Sugiyama; Koji Atarashi; Yuka Maeda; Masahide Hamaguchi; Naganari Ohkura; Eiichi Sato; Hirotsugu Nagase; Junichi Nishimura; Hirofumi Yamamoto; Shuji Takiguchi; Takeshi Tanoue; Wataru Suda; Hidetoshi Morita; Masahira Hattori; Kenya Honda; Masaki Mori; Yuichiro Doki; Shimon Sakaguchi
Journal:  Nat Med       Date:  2016-04-25       Impact factor: 53.440

10.  Emerging concepts of T cell metabolism as a target of immunotherapy.

Authors:  Chih-Hao Chang; Erika L Pearce
Journal:  Nat Immunol       Date:  2016-04       Impact factor: 25.606
View more
  3 in total

1.  Down-regulation of EOMES drives T-cell exhaustion via abolishing EOMES-mediated repression of inhibitory receptors of T cells in liver cancer.

Authors:  Hongwei He; Yong Yi; Xiaoyan Cai; Jiaxing Wang; Xiaochun Ni; Yipeng Fu; Shuangjian Qiu
Journal:  J Cell Mol Med       Date:  2020-12-16       Impact factor: 5.310

Review 2.  Mechanisms of resistance to immune checkpoint inhibitors.

Authors:  Joji Nagasaki; Takamasa Ishino; Yosuke Togashi
Journal:  Cancer Sci       Date:  2022-07-30       Impact factor: 6.518

3.  Human regulatory T cells (Treg) and their response to cancer.

Authors:  Theresa L Whiteside
Journal:  Expert Rev Precis Med Drug Dev       Date:  2019-07-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.